MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Change in fair value of derivati...
Stock-based compensation
Other payables and accrued liabi...
Others
Negative Cash Flow Breakdown
Accrued liability - related part...
Accounts payable - related party
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,306,339
-2,292,064
-613,174
-4,801,149
Stock-based compensation
145,298
146,714
148,360
152,421
Change in fair value of derivative liabilities
222,092
108,627
-28,850
67,039
Prepaid expenses and other receivables
-51,783
-62,879
-104,228
232,968
Accounts payable - related party
-6,715
-539,834
549,150
-2,523
Other payables and accrued liabilities
76,477
-59,332
162,799
-35,152
Accrued liability - related party
-
-4,125,000
-500,000
4,125,000
Franchise tax payable
-
-
0
0
Income tax payables
-
-
0
0
Accrued liability - related party
-4,088,334
-
-
-
Net cash used in operating activities
-1,780,738
-6,698,010
-177,487
-727,332
Payments of transactions cost
0
758,882
64,821
12,652
Proceeds received from issuance of common stock, prefunded warrants and common stock warrants for registered direct offering
0
7,999,988
0
1,050,000
Purchase of treasury stock
-
-
0
0
Proceeds received from exercise of prefunded warrants
4
6
-
-
Net cash provided by financing activities
4
7,241,112
-64,821
1,037,348
Net change in cash and cash equivalents
-1,780,734
543,102
-242,308
310,016
Cash and cash equivalents at beginning of the period
1,927,404
1,384,302
1,626,610
916,916
Cash and cash equivalents at end of the period
146,670
1,927,404
1,384,302
1,626,610
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds received from
exercise of prefunded...
$4
Net cash provided by
financing activities
$4
(-100.00%↓ Y/Y)
Net change in cash
and cash...
-$1,780,734
(-545.54%↓ Y/Y)
Canceled cashflow
$4
something is missing
$4,125,000
Change in fair value of
derivative liabilities
$222,092
Stock-based compensation
$145,298
(-54.34%↓ Y/Y)
Other payables and
accrued liabilities
$76,477
(184.05%↑ Y/Y)
Prepaid expenses and
other receivables
-$51,783
(90.75%↑ Y/Y)
Net cash used in
operating activities
-$1,780,738
(-102.16%↓ Y/Y)
Canceled cashflow
$4,620,650
Accrued liability -
related party
-$4,088,334
(-168.35%↓ Y/Y)
Net loss
-$2,306,339
(69.85%↑ Y/Y)
Accounts payable -
related party
-$6,715
(-280.56%↓ Y/Y)
Buy us a coffee
Estrella Immunopharma, Inc. (ESLAW)
Estrella Immunopharma, Inc. (ESLAW)